Anaplastic Large Cell Lymphoma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017 - Product Image

Anaplastic Large Cell Lymphoma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

  • ID: 4449823
  • Report
  • Region: Global
  • 128 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Ignyta, Inc.
  • Morphotek
  • Seattle Genetics, Inc.
  • MORE
Lymphoma is a cancer type where uncontrollable growth of lymphocytes (WBCs) initiating from lymph glands or lymphatic tissue or other parts of the lymphatic system, including bone marrow, tonsils, testicles, spleen and lymph nodes.

This excess growth of lymphocytes often accumulates in lymph nodes. Though this accumulation can occur in any body part, commonly affected parts are armpits, neck and groin and rarely in lungs or bones.

The non- inheritable and non- contageous disease is one of the common types of cancer but can be treated with patients’ life expectancy remaining quite large post- treatment.

Genomic alterations in lymphocytes cause damage to the lifecycle of these cells, boosting the cell division rate or affecting the death period. However, causes for such gene changes are yet to be determined.

Phases:
Phases of Lymphoma cancer
  • Single group of lymph nodes (above or below diaphragm)
  • Multiple group of lymph nodes are affected(above or below diaphragm)
  • Expands to both sides of diaphragm
  • Expands to bone marrow or other body parts
Types of Lymphoma Cancer

Though two types of Lymphoma are defined, it is often difficult to determine the exact sub- type of Lymphoma.

* Hodgkin Lymphoma
In Hodgkin Lymphoma, the cancer cells called Reed- Sternberg (RS) cells, have a characteristic appearance under microscope.
Further subtypes-

Nodular Sclerosis: Lymph nodes contain Reed- Sternberg cells mixed with normal white blood cells

Mixed Cellularity: Lymph nodes contain several Reed- Sternberg cells in addition to several other cell types

Lymphocyte- rich: Lymph nodes contain several normal- appearing lymphocytes and classic Reed- Sternberg cells

Lymphocyte- depleted: Lymph nodes contain large volume of Reed- Sternberg cells and few normal lymphocytes

Nodular lymphocyte- predominant Hodgkin lymphoma: Lymph nodes contain several abnormal B cells and Reed- Sternberg cells are rarely observed

* Non- Hodgkin Lymphoma
Unlike Hodgkin Lymphoma, the cancer cells called Reed- Sternberg cells are absent in this subtype of Lymphoma

High grade NHL

* B- cell NHL Lymphoma
Diffuse large B- cell (DLBCL): Abnormal growth of large B- Cells in different body parts

Intravascular B- Cell: Occurs due to explosion of lymphocytes within tiny vessels with no involvement of the organ parenchyma

Primary mediastinal large B- cell: Large neoplastic cells with B- cell derivation are observed

Burkitt: Most aggressive form, classified as endemic (African) type, sporadic type and HIV related

Primary central nervous system: DLBCL sub- type affecting the brain and or spinal cord

* T- cell NHL Lymphoma
Peripheral T- cell (PTCL NOS): Abnormal growth of T- cells which are not specified under any category

Anaplastic large cell: It can occur in the skin or in other organs throughout the body

Angioimmunoblastic T- cell: the body’s immune system does not recognize, and consequently destroys, its own cells and tissues

Enteropathy- associated: occurs in the intestines and is mostly associated with celiac disease

Nasal- type NK/T- cell: Natural killer cells often affecting the nasal area, trachea, gastrointestinal tract, or skin

Hepatosplenic T- cell: Abnormal growth of T- cells in liver or spleen

Lymphoblastic: The T- cells outgrow in number when a bone marrow cell develops alterations in its gene code

Low Grade NHL
Follicular: B- cells are affected; Enlargement of the lymph nodes in the neck, underarm, stomach, groin

Small lymphocytic: B- lymphocytes, with enlarged nodes affecting neck, armpit or groin

Lympho- plasmacytic: Enlarged cells make varying volumes of immunoglobin M protein in the blood, making it thick (condition referred to as Waldenstrom macroglobulinemi)

MALT Lymphoma (Gastric and Non- gastric): mucosa- associated lymphoid tissue (MALT) starts outside lymph nodes, usually in lymphatic tissue in the mucous membranes or tissues lining organs

Splenic marginal zone: The NHL sub- type affects spleen, bone marrow and blood

Nodal marginal zone: Mostly occurs in lymph nodes and rarely in spleen or bone marrow
Anaplastic Large Cell Lymphoma clinical trials report provides comprehensive analysis and trends in global Anaplastic Large Cell Lymphoma disease clinical trials. The research work analyzes the evolution of Anaplastic Large Cell Lymphoma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Anaplastic Large Cell Lymphoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Anaplastic Large Cell Lymphoma clinical trials.

Major drugs under development in Anaplastic Large Cell Lymphoma are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report
  • Number of Anaplastic Large Cell Lymphoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Anaplastic Large Cell Lymphoma
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Anaplastic Large Cell Lymphoma clinical trials worldwide are listed
Reasons to Buy
  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ignyta, Inc.
  • Morphotek
  • Seattle Genetics, Inc.
  • MORE
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
High grade NHL
Low Grade NHL
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010- 2017
2.2.3 Prominent Companies in Global Anaplastic Large Cell Lymphoma Trials, 2010- 2017

3 Anaplastic Large Cell Lymphoma Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for Anaplastic Large Cell Lymphoma
3.2 Anaplastic Large Cell Lymphoma Product Snapshots
3.2.1 Anaplastic Large Cell Lymphoma Drug Profiles

4 Global Anaplastic Large Cell Lymphoma Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010- 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010- 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010- 2017
4.4 Subjects Recruited by Region, 2010- 2017
4.5 Clinical Trials by Year, 2010- 2017
4.6 Subjects Recruited by Year, 2010- 2017
4.7 Clinical Trials by Development Phase, 2010- 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010- 2017
4.9 Clinical Trials by Status, 2010- 2017
4.10 Subjects Recruited by Trial Status, 2010- 2017
4.11 Clinical Trials by Sponsor Type, 2010- 2017
4.12 Subjects Recruited by Sponsor Type, 2010- 2017
4.13 Clinical Trials by Economy Type, 2010- 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010- 2017

5 Europe Anaplastic Large Cell Lymphoma Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Europe, 2010- 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010- 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010- 2017
5.4 Europe, Clinical Trials by Development Phase, 2010- 2017
5.5 Europe, Clinical Trials by Trial Status, 2010- 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010- 2017

6 North America Anaplastic Large Cell Lymphoma Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in North America, 2010- 2017
6.1.1 North America, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in North America, 2010- 2017
6.2.1 North America, Total Enrolment by Country
6.3 North America, Clinical Trials by Year, 2010- 2017
6.4 North America, Clinical Trials by Development Phase, 2010- 2017
6.5 North America, Clinical Trials by Trial Status, 2010- 2017
6.6 North America, Clinical Trials by Sponsor Type, 2010- 2017

7 South and Central America Anaplastic Large Cell Lymphoma Clinical Trial Research Trends

8 Western Pacific Anaplastic Large Cell Lymphoma Clinical Trial Research Trends
8.1 Clinical Trials by Top Countries in Western Pacific, 2010- 2017
8.1.1 Western Pacific, Clinical Trials by Country
8.2 Subjects Recruited by Top Countries in Western Pacific, 2010- 2017
8.2.1 Western Pacific, Total Enrolment by Country
8.3 Western Pacific, Clinical Trials by Year, 2010- 2017
8.4 Western Pacific, Clinical Trials by Development Phase, 2010- 2017
8.5 Western Pacific, Clinical Trials by Trial Status, 2010- 2017
8.6 Western Pacific, Clinical Trials by Sponsor Type, 2010- 2017

9 Recent Clinical Trials- Snapshots
9.1 Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
9.2 Anaplastic Large Cell Lymphoma Trial Snapshots- 2016
9.3 Anaplastic Large Cell Lymphoma Trial Snapshots- 2015
9.4 Anaplastic Large Cell Lymphoma Trial Snapshots- 2014
9.5 Anaplastic Large Cell Lymphoma Trial Snapshots- 2013
9.6 Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
9.7 Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
9.8 Anaplastic Large Cell Lymphoma Trial Snapshots- 2010

10 Appendix
10.1 About the Author
10.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Anaplastic Large Cell Lymphoma- Average Enrolment by Country, 2010- 2017
Figure 2: Anaplastic Large Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 3: Anaplastic Large Cell Lymphoma- Country wise Recruiting Sites, 2010- 2017
Figure 4: Anaplastic Large Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 5: Global Anaplastic Large Cell Lymphoma Clinical Trials Participation Share by Region, 2010- 2017
Figure 6: Global Anaplastic Large Cell Lymphoma Subjects Recruited by Region, 2010- 2017
Figure 7: Global Anaplastic Large Cell Lymphoma Clinical Trials by Year, 2010- 2017
Figure 8: Global Anaplastic Large Cell Lymphoma Subjects Recruited by Year, 2010- 2017
Figure 9: Global Anaplastic Large Cell Lymphoma Trials by Phase, 2010- 2017
Figure 10: Global Anaplastic Large Cell Lymphoma- Subjects Recruited by Phase, 2010- 2017
Figure 11: Global Anaplastic Large Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 12: Global Anaplastic Large Cell Lymphoma- Subjects Recruited by Trial Status, 2010- 2017
Figure 13: Global Anaplastic Large Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 14: Global Anaplastic Large Cell Lymphoma- Subjects Recruited by Trial Status, 2010- 2017
Figure 15: Global Anaplastic Large Cell Lymphoma- Clinical Trials by Type of Economy, 2010- 2017
Figure 16: Europe Anaplastic Large Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 17: Europe Anaplastic Large Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 18: Europe Anaplastic Large Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 19: Europe Anaplastic Large Cell Lymphoma Trials by Phase, 2010- 2017
Figure 20: Europe Anaplastic Large Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 21: Europe Anaplastic Large Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 22: North America Anaplastic Large Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 23: North America Anaplastic Large Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 24: North America Anaplastic Large Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 25: North America Anaplastic Large Cell Lymphoma Trials by Phase, 2010- 2017
Figure 26: North America Anaplastic Large Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 27: North America Anaplastic Large Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017
Figure 28: Western Pacific Anaplastic Large Cell Lymphoma- Country wise Clinical Trials, 2010- 2017
Figure 29: Western Pacific Anaplastic Large Cell Lymphoma- Country wise Subjects Recruited, 2010- 2017
Figure 30: Western Pacific Anaplastic Large Cell Lymphoma- Year wise Clinical Trials, 2010- 2017
Figure 31: Western Pacific Anaplastic Large Cell Lymphoma Trials by Phase, 2010- 2017
Figure 32: Western Pacific Anaplastic Large Cell Lymphoma- Clinical Trials by Recruitment Status, 2010- 2017
Figure 33: Western Pacific Anaplastic Large Cell Lymphoma- Clinical Trials by Sponsor Type, 2010- 2017

1.2 List of Tables
Table 1: Anaplastic Large Cell Lymphoma Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: Anaplastic Large Cell Lymphoma- Region wise Clinical Trials, 2010- 2017
Table 3: Anaplastic Large Cell Lymphoma- Region wise Subjects Recruited, 2010- 2017
Table 4: Global Anaplastic Large Cell Lymphoma- Clinical Trials and Subjects by Trial Type, 2010- 2017
Table 5: Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
Table 6: Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
Table 7: Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
Table 8: Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
Table 9: Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
Table 10: Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
Table 11: Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
Table 12: Anaplastic Large Cell Lymphoma Trial Snapshots- 2017
Table 13: Anaplastic Large Cell Lymphoma Trial Snapshots- 2016
Table 14: Anaplastic Large Cell Lymphoma Trial Snapshots- 2016
Table 15: Anaplastic Large Cell Lymphoma Trial Snapshots- 2016
Table 16: Anaplastic Large Cell Lymphoma Trial Snapshots- 2015
Table 17: Anaplastic Large Cell Lymphoma Trial Snapshots- 2015
Table 18: Anaplastic Large Cell Lymphoma Trial Snapshots- 2015
Table 19: Anaplastic Large Cell Lymphoma Trial Snapshots- 2015
Table 20: Anaplastic Large Cell Lymphoma Trial Snapshots- 2015
Table 21: Anaplastic Large Cell Lymphoma Trial Snapshots- 2015
Table 22: Anaplastic Large Cell Lymphoma Trial Snapshots- 2015
Table 23: Anaplastic Large Cell Lymphoma Trial Snapshots- 2014
Table 24: Anaplastic Large Cell Lymphoma Trial Snapshots- 2014
Table 25: Anaplastic Large Cell Lymphoma Trial Snapshots- 2014
Table 26: Anaplastic Large Cell Lymphoma Trial Snapshots- 2014
Table 27: Anaplastic Large Cell Lymphoma Trial Snapshots- 2014
Table 28: Anaplastic Large Cell Lymphoma Trial Snapshots- 2014
Table 29: Anaplastic Large Cell Lymphoma Trial Snapshots- 2013
Table 30: Anaplastic Large Cell Lymphoma Trial Snapshots- 2013
Table 31: Anaplastic Large Cell Lymphoma Trial Snapshots- 2013
Table 32: Anaplastic Large Cell Lymphoma Trial Snapshots- 2013
Table 33: Anaplastic Large Cell Lymphoma Trial Snapshots- 2013
Table 34: Anaplastic Large Cell Lymphoma Trial Snapshots- 2013
Table 35: Anaplastic Large Cell Lymphoma Trial Snapshots- 2013
Table 36: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 37: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 38: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 39: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 40: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 41: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 42: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 43: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 44: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 45: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 46: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 47: Anaplastic Large Cell Lymphoma Trial Snapshots- 2012
Table 48: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 49: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 50: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 51: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 52: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 53: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 54: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 55: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 56: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 57: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 58: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 59: Anaplastic Large Cell Lymphoma Trial Snapshots- 2011
Table 60: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 61: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 62: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 63: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 64: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 65: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 66: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 67: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 68: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 69: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 70: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 71: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Table 72: Anaplastic Large Cell Lymphoma Trial Snapshots- 2010
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Millennium Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company
  • Seattle Genetics, Inc.
  • Ignyta, Inc.
  • Arbeitsgemeinschaft medikamentoese Tumortherapie
  • Morphotek
  • Spectrum Pharmaceuticals, Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll